US 12,402,867 B2
Hemostatic biopsy tract article
Hiep Do, Chandler, AZ (US); and Jordan Addison, Gilbert, AZ (US)
Assigned to C.R. Bard, Inc., Murray Hill, NJ (US)
Appl. No. 17/428,797
Filed by C.R. Bard, Inc., Franklin Lakes, NJ (US)
PCT Filed Feb. 15, 2019, PCT No. PCT/US2019/018292
§ 371(c)(1), (2) Date Aug. 5, 2021,
PCT Pub. No. WO2020/167319, PCT Pub. Date Aug. 20, 2020.
Prior Publication US 2022/0000459 A1, Jan. 6, 2022
Int. Cl. A61B 90/00 (2016.01); A61B 10/02 (2006.01); A61L 31/04 (2006.01); A61L 31/14 (2006.01); C08L 1/28 (2006.01); C08L 3/04 (2006.01); C08L 5/08 (2006.01)
CPC A61B 10/0275 (2013.01) [A61B 90/39 (2016.02); A61L 31/041 (2013.01); A61L 31/146 (2013.01); A61L 31/148 (2013.01); C08L 1/286 (2013.01); C08L 3/04 (2013.01); C08L 5/08 (2013.01); A61B 2090/3908 (2016.02); A61L 2400/04 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A hemostatic biopsy tract article, comprising a bioresorbable body having a microporous structure, the bioresorbable body being formed by a mixture that includes a bioabsorbable hemostatic powder in an amount of 4% to 7% by weight/volume, wherein the bioresorbable hemostatic powder is an unhydrolyzed, plant-based starch, a hydrolyzed starch in an amount of 2% to 4% by weight/volume, hyaluronic acid in an amount of 0.3% to 1.3% by weight/volume, and carboxymethylcellulose in an amount of 0.3% to 1.3% by weight/volume and water, wherein the microporous structure has a pore size from 20 nanometers to 5 microns, wherein the microporous structure is formed by removing water by a sublimation or freeze-drying process.